Safety of tocilizumab in the treatment of juvenile idiopathic arthritis

References

• Kahn PJ. Juvenile idiopathic arthritis – what the clinician needs to know. Bull Hosp Jt Dis. 2013;71:194–199.
   Google Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149. Epub 2011/06/21.
   PubMed Web of Science ®Google Scholar
• Makay B, Unsal E, Kasapcopur O. Juvenile idiopathic arthritis. World J Rheumatol. 2013;12:16–24.
   Google Scholar
• Wong SC, MacRae VE, Gracie JA, et al. Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res. 2008;18:369–378. Epub 2008/04/02.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991–1994. Epub 1998/10/21.
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392. Epub 2004/02/05.
   PubMed Web of Science ®Google Scholar
• Dueckers G, Guellac N, Arbogast M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142:176–193. Epub 2011/12/14.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:13. Epub 2014/05/02.
   PubMed Web of Science ®Google Scholar
• Haines KA. Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis. 2007;65:205–211. Epub 2007/10/10.
   PubMedGoogle Scholar
• Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27:505–510. Epub 2015/07/07.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–294. Epub 2014/04/26.
   PubMed Web of Science ®Google Scholar
• Souza LS, Machado SH, Brenol CV, et al. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J Rheumatol. 2008:35:2265-2271. Epub 2008/10/10.
   Web of Science ®Google Scholar
• MacRae VE, Wong SC, Farquharson C, et al. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med. 2006;18:1011–1018. Epub 2006/11/08.
   PubMed Web of Science ®Google Scholar
• Pass C, MacRae VE, Ahmed SF, et al. Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth. Cell Biochem Funct. 2009;27:119–127. Epub 2009/03/31.
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851–856. Epub 1993/02/15.
   PubMed Web of Science ®Google Scholar
• Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009;21:224–230. Epub 2009/04/15.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61. Epub 1999/12/23.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50. Epub 2012/05/09.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209. Epub 1997/07/01.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23. Epub 2016/04/20.
   PubMed Web of Science ®Google Scholar
• Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15:931–934. Epub 2016/07/10.
   PubMed Web of Science ®Google Scholar
• Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep. 2014;6:21. Epub 2014/04/26.
   PubMedGoogle Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis & Rheumatism. 2005;52(3):818–825.
   PubMed Web of Science ®Google Scholar
• Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. Epub 2005/11/10.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22:109–115. Epub 2011/06/15.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. Epub 2008/03/25.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. Epub 2012/12/21.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117. Epub 2014/05/20.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660. Epub 2015/12/09.
   PubMed Web of Science ®Google Scholar
• Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17:66. Epub 2015/09/20.
   PubMed Web of Science ®Google Scholar
• Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55:669–679. Epub 2015/12/03.
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Ott De Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–1712. Epub 2011 Aug 3.
   PubMed Web of Science ®Google Scholar
• Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17:46.
   PubMed Web of Science ®Google Scholar
• Matsui T, Komiya A, Shimada K, et al. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol. 2009;19:696–697.
   PubMed Web of Science ®Google Scholar
• Hoffmann JJ. Neutrophil CD64: a diagnostic marker for infection and sepsis. Clin Chem Lab Med. 2009;47:903–916.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712–722. Epub 2015 Feb 15.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277–292.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al.. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis. 2016;75:68–74. Epub 2015 Jun 8.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Wallace T, Olech E, et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther. 2016;3:291–304. Epub 2016 Sep 24.
   PubMed Web of Science ®Google Scholar
• Liu X, Jones GW, Choy EH, et al. The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. 2016;28:152–160.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. Epub 2015 Dec 3.
   PubMed Web of Science ®Google Scholar